Enteric-Coated Oral SARS-CoV-2 Tablets for Respiratory Transmission Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reducing SARS-CoV-2 transmission, such as social distancing, face masks, and vaccinations, are becoming ineffective due to the increasing transmissibility of respiratory mutants, and are burdensome for economically distressed populations, with intramuscular vaccines causing serious side effects and limited long-term immunity.
Innovation Solution
The method involves preparing nasopharyngeal and oral materials for oral inoculation with SARS-CoV-2 using mammalian cells to produce viral particles, which are then formulated into enteric-coated tablets or rectal suppositories to induce intestinal infection, promoting alveolar defense and reducing respiratory transmission without systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intramuscular vaccines are used, then immunity is provided, but serious side effects occur and long-term immunity is limited
Solution Approach 1:
The patent changes the administration parameter from intramuscular injection to oral ingestion, fundamentally altering how the vaccine is delivered. This parameter change allows the vaccine to be taken as a liquid or tablet form through the digestive system, avoiding the serious side effects associated with intramuscular injections while maintaining immunity effectiveness.
Solution Approach 2:
The patent uses the digestive system as an intermediary medium to deliver the vaccine. Instead of direct intramuscular injection, the vaccine is administered through oral intake and utilizes the gastrointestinal tract as a mediator to transport the viral particles to the intestine, where they induce immunity without causing the severe side effects of traditional vaccines.
2Reliability
If social distancing and face masks are used, then transmission is reduced, but economic burden and social isolation increase
Solution Approach 1:
The patent converts the harmful factor of viral transmission into a beneficial immune response. By allowing controlled exposure to the virus through oral administration, the vaccine induces immunity that prevents future infections and transmissions, effectively converting the harmful viral particles into a protective benefit without the economic and social burdens of traditional mitigation strategies.
3Reliability
If respiratory transmission control methods are used, then spread is reduced, but transmissibility of mutants increases
Solution Approach 1:
The patent applies preliminary action by administering the vaccine before infection occurs. The oral administration of viral particles induces immunity in advance, creating protective antibodies that prevent subsequent infections and mutations. This preliminary immune priming counteracts the increasing transmissibility of respiratory mutants by establishing immunity before exposure to mutated strains.
Data Source
AI summary
The instant disclosure relates generally to oral inoculation and specifically to methods to prepare nasopharyngeal and oral material for oral inoculation of COVID-19. Severe acute respiratory syndrome coronavirus 2 (“SARS-CoV-2”) viral particles are collected from at least one of a nasopharyngeal specimen and an oral specimen each derived from a patient infected with SARS-CoV-2 or a SARS-CoV-2 variant. Mammalian cells (e.g., Vero-E6 and/or Vero-CCL81 cells) are infected with the SARS-CoV-2 viral particles to produce infected mammalian cells. The infected mammalian cells are cultured to produce a mammalian cell culture. SARS-CoV-2 viral particles are collected from the mammalian cell culture to produce isolated viral particles. The isolated viral particles are frozen to produce a frozen isolate. The frozen isolate is partitioned into a plurality of tablets each having a therapeutically effective amount of the SARS-CoV-2 viral particles. An enteric coating is applied to each tablet.